title: HIV-related Kaposi's Sarcoma with Musculoskeletal Involvement in the Modern Antiretroviral Era.
abstract: OBJECTIVE
  To describe the patterns of disease and clinical outcomes of MSK-KS in people living with HIV in the era of (combination anti-retroviral therapy cART).
  
  
  METHODS
  We reviewed our prospectively collected dataset of patients with HIV with biopsy-proven KS; 17 out of 1,489 seropositive patients were identified with subsequent evidence of MSK involvement by KS. We collected data with regards to clinicopathological parameters and radiological patterns of disease.
  
  
  RESULTS
  Fourteen patients (82.4%) had AIDS Clinical Trials Group T1 stage disease at presentation including four (23.5%) with non-nodal visceral disease. At the time of MSK-KS diagnosis, more than 80% of 14 patients had excellent HIV control. The median interval between initial KS to MSK-KS diagnosis was 3.3 years. Five-year overall survival rate from initial KS diagnosis was 76%, and 60% from MSK-KS diagnosis. The majority of patients were asymptomatic and MSK-KS involvement was demonstrated during imaging prompted by progression of their mucocutaneous KS. The majority of lesions were lytic with cortical involvement on cross-sectional imaging, whereas a soft-tissue component was commonly associated with long-bone involvement.
  
  
  CONCLUSIONS
  MSK-KS continues to be a rare entity in the modern era of cART, however patients appear to experience significantly improved survival.
authors.affiliation: Department of Oncology, Chelsea & Westminster Hospital, London, U.K.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Papanastasopoulos
authors.affiliation: Department of Oncology, Chelsea & Westminster Hospital, London, U.K.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Annan
authors.affiliation: Department of Oncology, Chelsea & Westminster Hospital, London, U.K.
authors.forename: Alessia
authors.initials: A
authors.lastname: Dalla Pria
authors.affiliation: Department of Oncology, Chelsea & Westminster Hospital, London, U.K. m.bower@imperial.ac.uk.
authors.forename: Mark
authors.initials: M
authors.lastname: Bower
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy / Q000821:virology; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D019042:Muscle Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy / Q000821:virology; D012514:Sarcoma, Kaposi / Q000401:mortality / Q000556:secondary* / Q000628:therapy / Q000821:virology; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents
keywords: HIV; Kaposi's sarcoma; antiretrovirals; musculoskeletal